Medicare and Medicaid spent more than $18 billion over four years on accelerated approval drugs with late post-market trials that are meant to confirm the drugs work, according to the HHS Inspector General, which released its findings the same day the Senate passed FDA user fee legislation from which accelerated approval reforms were stripped. FDA accelerated approvals allow sales of promising treatments for serious illnesses before clinical trials confirm they work. That process is being scrutinized after FDA approved the...